I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Kim Janda Biography and Net Worth

Director of Sorrento Therapeutics

Dr. Janda has served as a director since April 2012. Dr. Janda has been the Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute (“TSRI”) since 1996 and as the Director of the Worm Institute of Research and Medicine (“WIRM”) at TSRI since 2005. Furthermore, Dr. Janda has served as a Skaggs Scholar within the Skaggs Institute of Chemical Biology, also at TSRI, since 1996.

Dr. Janda has published more than 425 original publications in peer-reviewed journals and founded the biotechnological companies CombiChem, Drug Abuse Sciences and AIPartia. Dr. Janda is an associate editor of “Bioorganic & Medicinal Chemistry”, “PLoS ONE” and serves, or has served, on editorial boards of numerous journals including J. Comb. Chem., Chem. Reviews, J. Med. Chem., The Botulinum Journal, Bioorg. & Med. Chem. Lett., and Bioorg. & Med. Chem.

Over a career of more than 25 years, Dr. Janda has provided numerous seminal contributions and is considered one of the first scientists to merge chemical and biological approaches into a cohesive research program. Dr. Janda has served on the Scientific Advisory Boards of Materia and Singapore Ministry of Education.

Dr. Janda holds a B.S. degree from the University of South Florida in Clinical Chemistry and his Ph.D. from the University of Arizona with Robert B. Bates in Natural Product Total Synthesis.

What is Kim D. Janda's net worth?: The estimated net worth of Kim D. Janda is at least $3.92 as of April 12th, 2021. Dr. Janda owns 4,900 shares of Sorrento Therapeutics stock worth more than $4 as of December 23rd. This net worth approximation does not reflect any other investments that Dr. Janda may own. Learn More about Kim D. Janda's net worth.
How do I contact Kim D. Janda?: The corporate mailing address for Dr. Janda and other Sorrento Therapeutics executives is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. Sorrento Therapeutics can also be reached via phone at (858) 203-4100 and via email at [email protected]. Learn More on Kim D. Janda's contact information.
Has Kim D. Janda been buying or selling shares of Sorrento Therapeutics?: Kim D. Janda has not been actively trading shares of Sorrento Therapeutics within the last three months. Most recently, Kim Janda sold 3,000 shares of the business's stock in a transaction on Monday, December 27th. The shares were sold at an average price of $5.88, for a transaction totalling $17,640.00. Learn More on Kim D. Janda's trading history.

Kim D. Janda Insider Trading History at Sorrento Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/27/2021	Sell	3,000	$5.88	$17,640.00
9/27/2021	Sell	42,357	$8.02	$339,703.14
9/13/2021	Sell	8,000	$8.04	$64,320.00
4/12/2021	Sell	1,900	$6.97	$13,243.00	4,900

Kim D. Janda Buying and Selling Activity at Sorrento Therapeutics

Sorrento Therapeutics Company Overview

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Today's Range

Now: $0.00

$0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00

$0.00

$0.18

Volume

231,676 shs

Average Volume

279,417 shs

Market Capitalization

$441,024.80

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now